[go: up one dir, main page]

MA56286A1 - Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r? - Google Patents

Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r?

Info

Publication number
MA56286A1
MA56286A1 MA56286A MA56286A MA56286A1 MA 56286 A1 MA56286 A1 MA 56286A1 MA 56286 A MA56286 A MA 56286A MA 56286 A MA56286 A MA 56286A MA 56286 A1 MA56286 A1 MA 56286A1
Authority
MA
Morocco
Prior art keywords
immunocytokine
complex based
hetero
protein complex
dimer protein
Prior art date
Application number
MA56286A
Other languages
English (en)
Other versions
MA56286B1 (fr
Inventor
Stanislav Rudolfovich Evdokimov
Andrei Borisovich Ulitin
Sergei Andreevich Ageev
Ivan Vladimirovich Mitroshin
Alekseyvladimirovich Kononov
Aleksandr Andreevich Gordeev
Elena Vladimirovna Vinogradova
Aleksandra Pavlovna Shmakova
Dmitryvalentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA56286A1 publication Critical patent/MA56286A1/fr
Publication of MA56286B1 publication Critical patent/MA56286B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une immunocytokine comprenant un complexe hétéro-dimère protéinique à base de il-15/il-15ra, ainsi que son utilisation en qualité d'agent thérapeutique, notamment en qualité d'agent pour le traitement du cancer et d'une maladie auto-immune. La présente invention concerne également une immunocytokine comprenant un complexe hétéro-dimère protéinique à base de il-15/il-15ra et un anticorps immunomodulant, ainsi que son utilisation en qualité d'agent thérapeutique, notamment en qualité d'agent pour le traitement du cancer et d'une maladie auto-immune.
MA56286A 2019-09-19 2020-09-20 Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r? MA56286B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019129569A RU2753282C2 (ru) 2019-09-19 2019-09-19 ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
PCT/RU2020/050233 WO2021054867A1 (fr) 2019-09-19 2020-09-20 Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15rα

Publications (2)

Publication Number Publication Date
MA56286A1 true MA56286A1 (fr) 2023-05-31
MA56286B1 MA56286B1 (fr) 2023-09-27

Family

ID=74873995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56286A MA56286B1 (fr) 2019-09-19 2020-09-20 Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r?

Country Status (20)

Country Link
US (1) US20230011234A1 (fr)
EP (1) EP4032539A4 (fr)
JP (2) JP2022549276A (fr)
KR (1) KR20220145323A (fr)
CN (1) CN115297885A (fr)
AR (1) AR120011A1 (fr)
AU (1) AU2020351560A1 (fr)
BR (1) BR112022005173A2 (fr)
CA (1) CA3151780A1 (fr)
CO (1) CO2022003156A2 (fr)
JO (1) JOP20220071A1 (fr)
MA (1) MA56286B1 (fr)
MX (1) MX2022003306A (fr)
PE (1) PE20220603A1 (fr)
PH (1) PH12022550688A1 (fr)
RU (1) RU2753282C2 (fr)
TW (1) TWI891660B (fr)
UY (1) UY38889A (fr)
WO (1) WO2021054867A1 (fr)
ZA (1) ZA202203254B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CA3196844A1 (fr) 2020-11-25 2022-06-02 Raphael Rozenfeld Lieurs clivables specifiques aux tumeurs
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
CN116178572B (zh) * 2022-02-28 2025-12-23 厦门柏慈生物科技有限公司 构建嵌合蛋白的嵌合区域、构建方法、嵌合蛋白及其应用
CN115141283A (zh) * 2022-03-10 2022-10-04 厦门柏慈生物科技有限公司 一种融合蛋白、制备方法及其应用
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
WO2025031274A1 (fr) * 2023-08-04 2025-02-13 深圳众格生物科技有限公司 Mutant de domaine sushi, protéine de fusion, composition pharmaceutique et utilisation
WO2025140627A1 (fr) * 2023-12-28 2025-07-03 南通壹宸生物医药科技有限公司 Anticorps de fusion et son utilisation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (fr) 1985-04-01 1986-10-09 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotque employant cette lignee
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE272070T1 (de) * 1996-08-16 2004-08-15 Harvard College Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
NZ506071A (en) * 1998-02-19 2003-05-30 Harvard College Monovalent, multivalent, and multimeric major histocompatibility complex (MHC) binding domain fusion proteins and conjugates, and uses therefore
EP2295078A3 (fr) * 1999-12-23 2011-03-23 ZymoGenetics, L.L.C. Methode destinée à traiter l'inflammation
EP1777294A1 (fr) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
EP2160401B1 (fr) * 2007-05-11 2014-09-24 Altor BioScience Corporation Molécules de fusion et variantes de il-15
AU2011305476B2 (en) * 2010-09-21 2016-12-01 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
EP2537933A1 (fr) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
RU2019108429A (ru) * 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
BR112016002614B8 (pt) 2013-08-08 2023-11-07 Hopitaux Paris Assist Publique Imunocitoquina e composição farmacêutica
KR20160103058A (ko) * 2014-01-08 2016-08-31 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 Il-15 이종 이량체 단백질 및 그의 용도
CN106659775B (zh) * 2014-06-30 2021-08-06 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
SI3235830T1 (sl) 2014-12-19 2020-12-31 Jiangsu Hengrui Medicine Co., Ltd. Proteinski kompleks interlevkina 15 in njegove uporabe
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
UA128669C2 (uk) 2016-10-14 2024-09-25 Ксенкор, Інк. ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra
KR102392142B1 (ko) * 2016-10-21 2022-04-28 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
WO2018165208A1 (fr) * 2017-03-06 2018-09-13 Altor Bioscience Corporation Protéines de fusion à base d'il-15 spécifique à il-12 et il-18
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
EP3645122A1 (fr) * 2017-06-30 2020-05-06 Xencor, Inc. Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
US11471490B2 (en) * 2017-07-03 2022-10-18 Torque Therapeutics, Inc. T cells surface-loaded with immunostimulatory fusion molecules and uses thereof

Also Published As

Publication number Publication date
RU2753282C2 (ru) 2021-08-12
BR112022005173A2 (pt) 2022-08-16
WO2021054867A1 (fr) 2021-03-25
RU2019129569A3 (fr) 2021-03-19
CN115297885A (zh) 2022-11-04
AR120011A1 (es) 2022-01-26
CA3151780A1 (fr) 2021-03-25
TW202124420A (zh) 2021-07-01
PE20220603A1 (es) 2022-04-25
RU2019129569A (ru) 2021-03-19
UY38889A (es) 2021-04-30
JOP20220071A1 (ar) 2023-01-30
PH12022550688A1 (en) 2023-05-29
KR20220145323A (ko) 2022-10-28
JP2025182218A (ja) 2025-12-12
AU2020351560A1 (en) 2022-11-24
EP4032539A4 (fr) 2023-09-13
CO2022003156A2 (es) 2022-04-19
JP2022549276A (ja) 2022-11-24
EP4032539A1 (fr) 2022-07-27
MA56286B1 (fr) 2023-09-27
ZA202203254B (en) 2025-10-29
TWI891660B (zh) 2025-08-01
US20230011234A1 (en) 2023-01-12
MX2022003306A (es) 2022-04-26

Similar Documents

Publication Publication Date Title
MA56286A1 (fr) Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r?
EP1461081A4 (fr) Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon
DK1272515T3 (da) Immunregulator
BRPI0415505A (pt) agente terapêutico para mesotelioma
DE60220719D1 (de) Antikörper gegen das muc18-antigen
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA28149A1 (fr) Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
EA200400312A1 (ru) АНТАГОНИСТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFSF13b ЧЕЛОВЕКА
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
MXPA03008955A (es) Agente terapeutico para enfermedades de tipo artritides cronicas o enfermedades relacionadas con la ninez.
DK2065467T3 (da) Anti-interferon-alfa-antistoffer
BR0206364A (pt) Métodos para tratar doenças auto-imunes em um indivìduo e testes diagnósticos in vitro
WO2004078098A3 (fr) Peptides associes a des molecules hla-dr mhc de classe ii impliquees dans des maladies auto-immunes
SA522432487B1 (ar) مشتقات علاجية من إنترلوكين-22
ATE249835T1 (de) Immunoregulator
EE03697B1 (et) Interleukiin-1 retseptori antagonisti intratsellulaarne isovorm
BE588311A (fr) émulsions aqueuses lubrifiantes à base d'esters, utilisables en particulier pour le traitement de fibres de polyamides
MA32080B1 (fr) Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1
Mohyddin et al. A Comprative Study of Quranic & Non-Quranic Life
FR3143975B1 (fr) Phytoecdysones pour leur utilisation dans le traitement de pathologies respiratoires inflammatoires
TWD220136S (zh) 分析物量測裝置
Mantovani Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. By Declan Walsh et al. Supportive Care in Cancer (2003) 11: 60–62